Treeline Biosciences CSO Jeffrey Engelman (L) and CEO Josh Bilenker
October 17, 2022 09:11 AM EDTUpdated 09:26 AM
Financing
Startups

Josh Bilenker, Jeff En­gel­man qui­et on every­thing be­hind their $735M 'outer edge' start­up

Kyle LaHucik

Senior Reporter

An $8 bil­lion ex­it from Eli Lil­ly and a short-lived stint head­ing up on­col­o­gy work at the Big Phar­ma post-Loxo sale have per­suad­ed Josh …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times